Background: Inflammatory breast cancer (IBC) is the most aggressive form of breast cancer. Circulating tumor cells (CTCs) are an independent prognostic factor in metastatic breast cancer. The aim of this study was to assess the prognostic value of baseline CTCs in metastatic IBC patients. Results: Ten (23.8%) IBC patients versus 48 (44.9%) non-IBC patients had baseline CTCs ‡5 per 7.5 ml of peripheral blood. IBC patients had a lower mean 6 SEM CTCs than non-IBC patients (7.6 6 2.9 versus 34.2 6 9.1; P = 0.02). The estimated median overall survival was 26.5 versus 18.3 months (P = 0.68) in IBC patients and 37.4 versus 18.3 months (P = 0.016) in non-IBC patients with CTCs <5 and CTCs ‡5, respectively.
introduction
Inflammatory breast cancer (IBC) is a rare but most aggressive form of primary breast cancer with increasing incidence [1] . Despite a multimodality approach including chemotherapy, surgery, and radiation therapy, the prognosis of IBC remains poor with a 10-year disease-free survival rate of 20%-25% [2, 3] . These data clearly indicate that current treatment modalities are inadequate and emphasize the need for a better understanding of this disease.
IBC is associated with special clinical and biological features and distinctive pattern of recurrence [2, 4] . The aggressive nature of IBC is characterized by a high proliferation rate, frequent absence of estrogen receptor and progesterone receptor expression, high histological tumor grade, and increased tumor angiogenesis [5] [6] [7] . Study of several molecular factors in IBC indicates frequent human epidermal growth factor 2 (HER2) and epidermal growth factor receptor overexpression, and high levels of expression of p53 and MUC1, RhoC, and E-cadherin [8] [9] [10] [11] .
Circulating tumor cells (CTCs) are cancer cells of epithelial origin, whose detection before a new treatment represents an independent predictor of progression-free survival and overall survival (OS) in patients with metastatic breast cancer [12] . Superior survival among patients with <5 CTCs was observed regardless of histology, hormone receptor and HER2/neu status, sites of first metastasis, or whether the patient had recurrent or de novo metastatic disease [12, 13] . The prognostic value of CTCs was demonstrated to be superior to tumor burden as measured by Swenerton score or by serum tumor markers, indicating a special biological value of CTCs. These data also indicate the possibility that CTCs might represent a population of tumorigenic cancer cells and might play an important role in tumor dissemination [14] . However, due to the low incidence of IBC, data on the prognostic value of CTCs in IBC patients are very limited.
We hypothesized that CTCs should mirror aggressive clinical behavior of IBC and that CTCs might be associated with special clinical features of IBC-like dermal lymphatic invasion. In the present study, we investigated the prognostic value of baseline CTCs in metastatic IBC patients along with correlation to primary tumor biomarkers.
patients and methods

study patients
This study was conducted using MD Anderson Cancer Center medical records database. A population of consecutive metastatic breast cancer patients treated from January 2004 to December 2007 was eligible. Only patients with documented progressive disease starting treatment with first-or second-line chemotherapy were included to the study. All patients had CTC enumeration before starting a new treatment as standard of care. Patients underwent systemic therapy as appropriate for their malignancy irrespective of CTCs. Prior adjuvant or neoadjuvant treatment or both were permitted. Patients with concurrent malignancy other than nonmelanoma skin cancer in the previous 5 years were excluded.
All patients had undergone pretreatment diagnostic biopsy. The diagnosis of IBC was based on clinical signs such as diffuse erythema, peau d'orange, tenderness, induration, and warmth [15] . The presence of dermal lymphatic emboli in the diagnostic pathology report was not mandatory for the IBC group. Patients were required to have clinical and radiological evidence of metastatic breast cancer before initiating new line of chemotherapy.
In all patients, data regarding age, tumor histology, hormone receptor status, HER2 status, type and number of metastatic sites, and systemic therapy were recorded and compared with the presence of CTCs. The retrospective study was approved by the Institutional Review Board and a waiver of consent form was granted.
detection of CTCs in peripheral blood
The CellSearchä system (Veridex Corporation, Warren, NJ) was used to detect CTCs in 7.5 ml of whole peripheral blood. Samples were subject to enrichment with anti-EpCAM-coated beads. CTCs were defined as nucleated cells lacking CD45 but expressing cytokeratins 8, 18, or 19.
Specimens were stored at room temperature and processed within 1 day. A threshhold of 5 CTCs per 7.5 ml blood was used to evaluate results, with poor prognosis indicated by >5 CTCs and good prognosis defined as <5 CTCs [12] .
statistical analysis
Univariate analyses with chi-square or by the Fisher's exact test were carried out as appropriate. Median follow-up period was calculated as a median observation time among all patients and among those still alive at the time of their last follow-up. OS was calculated from the date of baseline CTCs measurement to the date of death or last follow-up and estimated using Kaplan-Meier product limit method and compared between groups by logrank test. All statistical tests were two sided and P values <0.05 were considered statistically significant.
results
We identified 149 patients (42 with IBC and 107 with non-IBC) who matched study eligibility criteria and were included in this analysis. The median age of the IBC patients and non-IBC patients at the time of CTCs measurement was 52 years (range 23-72 years) and 54 years (range 28-79 years), respectively. The majority of patients had infiltrative ductal histology (92%). Patients' characteristics and their associations with biomarkers are shown in Table 1 . IBC patients were more likely to have hormone receptor-negative (69.1% versus 40.1%, P = 0.002) and HER2-amplified disease (31% versus 20.6%, P = 0.178). Patients with non-IBC disease had more frequent evidence of visceral metastases (68.2% versus 57.1%, P = 0.2). None of the IBC patients with HER2-positive disease had ‡5 CTCs compared with 45.6% for non-IBC patients. Eight IBC (69%) and 10 non-IBC (45.6%) patients with HER2-amplified disease were pretreated by anti-HER2 therapy before CTC measurement (P = 0.29). In a subgroup of patients with <5 
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CTCs, 69% of IBC versus 58.3% of non-IBC patients received anti-HER2 therapy previously (P = 0.69).
Ten patients (23.8%) with IBC compared with 48 patients (44.9%) with non-IBC group had baseline ‡5 CTCs ‡5 per 7.5 ml of blood, respectively. IBC patients had a significantly lower baseline mean 6 SEM CTCs per 7.5 ml of blood than non-IBC patients (7.6 6 2.9 versus 34.2 6 9.1; P = 0.02); similar findings were demonstrated for the higher CTC values during the course of the disease (23. (Figures 1 and 2) .
discussion
This retrospective study based on the single-center experience indicates that metastatic IBC patients, despite aggressive disease, had a lower prevalence and fewer CTCs as measured by the CellSearch technology in comparison to non-IBC patients. In non-IBC group, patients with ‡5 CTCs constitute 44.9%, which is in the range reported in previous trials [12, 13] . We (Table 2) ; however, survival of IBC patients with <5 CTCs was markedly lower compared with that of the non-IBC group (median survival 26.5 versus 37.4 months, P = 0.39). In non-IBC patients, we confirmed the prognostic value of CTCs on patients' survival in whole group as well as in subgroup analyses. Several mechanisms might explain the low CTCs prevalence and the aggressive biological behavior of IBC, compared with non-IBC patients. First, despite lower prevalence, CTCs in IBC patients seem to be a prognostic factor but mirror only part of biological features of IBC. Other biological factors are probably more important in aggressive clinical behavior of IBC.
Secondly, IBC is characterized by florid tumor emboli within lymphovascular spaces termed lymphovascular invasion. It was demonstrated that the tumor cell embolus forms on the basis of an intact and overexpressed E-cadherin/alpha, beta-catenin axis which mediates tumor cell-tumor cell adhesion analogous to the embryonic blastocyst [16] . In IBC patients, collective dissemination of cancer cells via lymph vascular tumor emboli and not CTCs may be the preferred mechanism of micrometastasis. We observed that patients with <5 CTCs had more often dermal lymphatic emboli in comparison to patients with ‡5 CTCs and the main difference in survival between IBC and non-IBC group was restricted to patients with <5 CTCs. Thirdly, a number of studies indicate that carcinoma cells often activate a transdifferentiation program termed the epithelialmesenchymal transition (EMT) to acquire the ability to execute the multiple steps of the invasion-metastasis cascade [17] . During an EMT, epithelial cells acquire mesenchymal gene expression with decreased expression of epithelial markers [17] . These changes are accompanied with stem-cell phenotype and more aggressive behavior as well [18] . We speculate that EMT accompanied by a decrease in expression of epithelial markers may lead to impaired detection of CTCs using EpCAM as enrichment method and this may account for the observed difference.
HER2 overexpression is associated with a more aggressive course of the disease and previous studies indicate frequent HER2 overexpression in IBC patients, which was confirmed also by our study (30.9% in IBC versus 20.5% in non-IBC patients) [8, 19] . In previous studies, HER2 status of primary tumor correlated with the presence of CTCs in operable breast cancer patients [20, 21] . However, in metastatic breast cancer patients, HER2 status was not associated with increased number of CTCs [12, 13] . In addition, we observed that none of the patients with HER2-positive IBC had ‡5 CTCs in comparison to 45.6% cases with HER2-positive non-IBC. Previous anti-HER2 treatments were administered as either neoadjuvant/adjuvant or metastatic setting in 9 of 13 (69%) HER2-positive IBC patients, and in 10 of 22 (45%) HER2-positive non-IBC patients. In a recent paper, all patients but one with HER2-positive breast cancer treated with 
Annals of Oncology original article
trastuzumab-based regimens had normalized CTC counts at midtherapy [22] . Then, this observed difference could be in part justified by the effect of anti-HER2 therapy. Alternative explanation is that HER2 may participate in EMT induction in IBC patients with decrease in detection of CTCs; however, our results might be affected by low number of patients as well.
The main limitation of this trial is the retrospective nature of the analysis and therefore the study results are only hypothesis generating. Our results are applicable only to metastatic IBC patients who have already been treated and not to those with newly diagnosed disease. Sample size, heterogeneous patient population, and therapies might affect the study results as well. Other limitation is that patients were not monitored for CTC counts on a regular basis, and therefore it was not possible to assess the prognostic value of CTC kinetics during the course of the disease. On the other hand, majority of the patients in our analysis were treated according to daily clinical practice, which might increase generalizability of the results.
In conclusion, to our knowledge, this is the first study that assessed the prognostic value of CTCs in metastatic IBC patients. This large retrospective study indicates that metastatic IBC patients, despite aggressive disease, had a lower prevalence and fewer CTCs in comparison to non-IBC patients. We observed that metastatic IBC patients with <5 CTCs had a nonstatistically significant better survival than patients with ‡5 CTCs. Further research is warranted with prospective assessment of CTCs in IBC patients and their biological characterization. 
